A neurological biomarker is a substance that offers objective and quantifiable information regarding the presence, progression, or characteristics of a neurological disorder or condition. These biomarkers play a crucial role in clinical practice, particularly during drug development.
The main categories of neurological biomarkers include proteomics biomarkers, genomics biomarkers, metabolomics biomarkers, imaging biomarkers, and others. Proteomics biomarkers specifically involve proteins or patterns of proteins that can be identified and monitored by analyzing proteins in bodily fluids. These biomarkers find applications in various neurological conditions such as Alzheimer's disease, Parkinson's disease, Huntington's disease, schizophrenia, depression, multiple sclerosis, and spinal muscular atrophy. They are utilized by hospital laboratories, clinical diagnostic centers, research organizations, and other relevant entities.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The neurological biomarkers research report is one of a series of new reports from The Business Research Company that provides neurological biomarkers market statistics, including the neurological biomarkers industry's global market size, regional shares, competitors with neurological biomarkers market share, detailed neurological biomarkers market segments, market trends and opportunities, and any further data you may need to thrive in the neurological biomarkers industry. This neurological biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The neurological biomarkers market size has grown rapidly in recent years. It will grow from $10.7 billion in 2024 to $11.92 billion in 2025 at a compound annual growth rate (CAGR) of 11.4%. The growth in the historic period can be attributed to increasing prevalence of neurological disorders, aging population, drug development needs, increased funding for neurological research, personalized medicine.
The neurological biomarkers market size is expected to see rapid growth in the next few years. It will grow to $19.91 billion in 2029 at a compound annual growth rate (CAGR) of 13.7%. The growth in the forecast period can be attributed to biomarkers for early detection, biosensors, wearable devices, global health initiatives, patient-centric approach. Major trends in the forecast period include technological innovation in imaging, rapid advances in omics technologies, integration of artificial intelligence (AI), real-world evidence in biomarker validation, advancements in diagnostic technologies, collaboration between industry and research institutions.
The forecast of 13.7% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S. by increasing the cost of Cerebrospinal Fluid assay kits and tau protein detection reagents sourced from Switzerland and Japan, thereby delaying neurodegenerative disease diagnoses and elevating neurology lab expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The anticipated rise in the prevalence of neurological diseases is poised to drive the growth of the neurological biomarker market. Neurological illnesses impact the brain, spinal cord, and the body's nervous system. In the case of neurodegenerative disorders such as Parkinson's disease, neurological biomarkers play a crucial role in providing early diagnoses through pathological, biochemical, and genetic testing. As of December 2022, the Parkinson's Foundation reported an increase in new diagnoses of Parkinson's disease, reaching 90,000 in 2022 compared to 60,000 per year in 2021. This surge underscores the role of neurological biomarkers in addressing the growing prevalence of neurological diseases.
The increasing incidence of schizophrenia is expected to contribute to the growth of the neurological biomarkers market. Schizophrenia, a severe mental health disorder, presents cognitive, emotional, and behavioral symptoms. Neurological biomarkers offer the potential for early detection, objective diagnostic measures, personalized treatment, reduced reliance on subjective assessments, and a deeper understanding of the disorder's neurobiological mechanisms. Globally, approximately 24 million people, or 1 in 300 individuals (0.32%), suffer from schizophrenia, with adults experiencing this at a rate of one in 222 (0.4%), as reported by the World Health Organization in January 2022. This prevalence underscores the significance of neurological biomarkers in addressing conditions such as schizophrenia.
Major companies are forging partnerships to enhance innovation and solidify their market positions. For instance, in July 2022, NeuroSense Therapeutics Ltd., an Israel-based company developing treatments for severe neurodegenerative diseases partnered with NeuraLight, an Israel-based company developing objective and sensitive biomarkers for neurological disorders. This collaboration is to identify oculometric indicators for Amyotrophic Lateral Sclerosis (ALS) through the application of AI (Artificial Intelligence) and ML (Machine Learning). The partnership, which comes after NeuraLight's $25 million Series A financing, is to enhance the discovery and application of ALS digital indicators in a parallel study. This will be the collaboration's first clinical trial. The partnership is centered on the application of oculometric digital indicators, which may allow for patient classification and boost clinical trial success rates. Such collaborations facilitate the advancement and commercialization of novel therapies by combining resources and expertise.
Major companies in the neurological biomarkers market are developing innovative products, including advanced biomarker blood tests. For instance, in July 2023, Quanterix Corporation, a US-based company that specializes in the development and commercialization of ultra-sensitive digital immunoassay platforms launched the LucentAD biomarker blood test. This test, analyzing p-Tau 181 levels, aids medical professionals in evaluating patients with cognitive symptoms indicative of Alzheimer's disease. The test is positioned as a diagnostic tool for adults undergoing assessment for Alzheimer's disease but is not intended for standalone screening or diagnosis, emphasizing the need for a comprehensive diagnostic approach.
In April 2024, GE HealthCare, a US-based medical technology firm, acquired MIM Software Inc. for an undisclosed amount. GE HealthCare aims to enhance precision care by integrating advanced imaging analytics and streamlining workflows, ultimately improving patient outcomes and clinician efficiency. This strategic move positions GE HealthCare to provide more personalized treatment solutions across various medical specialties. MIM Software Inc., also a US-based company, specializes in medical imaging software and offers advanced imaging solutions that improve the identification and analysis of neurological biomarkers, aiding in the more effective diagnosis and monitoring of neurological disorders.
Major companies operating in the neurological biomarkers market include Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, Thermos Fisher Scientific Inc., AstraZeneca Plc, Abbott Laboratories, Boehringer Ingelheim International GmbH, Becton Dickinson and Company, Agilent Technologies Inc., Grifols S.A., Eisai Co. Ltd., PerkinElmer Inc., Illumina Inc., Shimadzu Corporation, Waters Corporation, Bio-Rad Laboratories Inc., Mallinckrodt Plc, Qiagen N.V., Luminex Corporation, Siemens Healthineers, Olink Proteomics, Meso Scale Diagnostics, Quanterix Corp., Fujirebio, Cisbio Bioassays SAS, NeuroVision Imaging, Proteome Sciences Plc, Acumen Pharmaceuticals.
North America was the largest region in the neurological biomarkers market in 2024. The regions covered in the neurological biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the neurological biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
The neurological biomarker market consists of sales of genetic testing kits, electroencephalography (EEG) devices, and biomarker assay kits. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Neurological Biomarkers Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on neurological biomarkers market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for neurological biomarkers ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The neurological biomarkers market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Product: Proteomics Biomarker; Genomics Biomarker; Metabolomics Biomarker; Imaging Biomarker; Other Products
- 2) By Application: Alzheimer's Disease; Parkinson's Disease; Huntington's Disease; Schizophrenia; Depression; Multiple Sclerosis; Spinal Muscular Atrophy
- 3) By End-User: Hospital Laboratories; Clinical Diagnostic Centers; Research Organizations; Other End-Users
- Subsegments:
- 1) By Proteomics Biomarker: Protein Biomarkers; Antibody Biomarkers
- 2) By Genomics Biomarker: DNA Biomarkers; RNA Biomarkers
- 3) By Metabolomics Biomarker: Metabolite Biomarkers; Lipid Biomarkers
- 4) By Imaging Biomarker: MRI Biomarkers; PET Scan Biomarkers
- 5) By Other Products: Neuroinflammatory Biomarkers; Neurotransmitter Biomarkers
- Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Merck & Co. Inc.; Novartis AG; Thermos Fisher Scientific Inc.; AstraZeneca Plc; Abbott Laboratories; Boehringer Ingelheim International GmbH; Becton Dickinson and Company; Agilent Technologies Inc.; Grifols S.A.; Eisai Co. Ltd.; PerkinElmer Inc.; Illumina Inc.; Shimadzu Corporation; Waters Corporation; Bio-Rad Laboratories Inc.; Mallinckrodt Plc; Qiagen N.V.; Luminex Corporation; Siemens Healthineers; Olink Proteomics; Meso Scale Diagnostics; Quanterix Corp.; Fujirebio; Cisbio Bioassays SAS; NeuroVision Imaging; Proteome Sciences Plc; Acumen Pharmaceuticals.
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time Series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Neurological Biomarkers Market Characteristics
3. Neurological Biomarkers Market Trends And Strategies
4. Neurological Biomarkers Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
- 4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Neurological Biomarkers Growth Analysis And Strategic Analysis Framework
- 5.1. Global Neurological Biomarkers PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Neurological Biomarkers Market Growth Rate Analysis
- 5.4. Global Neurological Biomarkers Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Neurological Biomarkers Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Neurological Biomarkers Total Addressable Market (TAM)
6. Neurological Biomarkers Market Segmentation
- 6.1. Global Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Proteomics Biomarker
- Genomics Biomarker
- Metabolomics Biomarker
- Imaging Biomarker
- Other Products
- 6.2. Global Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Alzheimer's Disease
- Parkinson's Disease
- Huntington's Disease
- Schizophrenia
- Depression
- Multiple Sclerosis
- Spinal Muscular Atrophy
- 6.3. Global Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospital Laboratories
- Clinical Diagnostic Centers
- Research Organizations
- Other End-Users
- 6.4. Global Neurological Biomarkers Market, Sub-Segmentation Of Proteomics Biomarker, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Protein Biomarkers
- Antibody Biomarkers
- 6.5. Global Neurological Biomarkers Market, Sub-Segmentation Of Genomics Biomarker, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- DNA Biomarkers
- RNA Biomarkers
- 6.6. Global Neurological Biomarkers Market, Sub-Segmentation Of Metabolomics Biomarker, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Metabolite Biomarkers
- Lipid Biomarkers
- 6.7. Global Neurological Biomarkers Market, Sub-Segmentation Of Imaging Biomarker, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- MRI Biomarkers
- PET Scan Biomarkers
- 6.8. Global Neurological Biomarkers Market, Sub-Segmentation Of Other Products, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Neuroinflammatory Biomarkers
- Neurotransmitter Biomarkers
7. Neurological Biomarkers Market Regional And Country Analysis
- 7.1. Global Neurological Biomarkers Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Neurological Biomarkers Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Neurological Biomarkers Market
- 8.1. Asia-Pacific Neurological Biomarkers Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Neurological Biomarkers Market
- 9.1. China Neurological Biomarkers Market Overview
- 9.2. China Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Neurological Biomarkers Market
- 10.1. India Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Neurological Biomarkers Market
- 11.1. Japan Neurological Biomarkers Market Overview
- 11.2. Japan Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Neurological Biomarkers Market
- 12.1. Australia Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Neurological Biomarkers Market
- 13.1. Indonesia Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Neurological Biomarkers Market
- 14.1. South Korea Neurological Biomarkers Market Overview
- 14.2. South Korea Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Neurological Biomarkers Market
- 15.1. Western Europe Neurological Biomarkers Market Overview
- 15.2. Western Europe Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Neurological Biomarkers Market
- 16.1. UK Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Neurological Biomarkers Market
- 17.1. Germany Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Neurological Biomarkers Market
- 18.1. France Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Neurological Biomarkers Market
- 19.1. Italy Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Neurological Biomarkers Market
- 20.1. Spain Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Neurological Biomarkers Market
- 21.1. Eastern Europe Neurological Biomarkers Market Overview
- 21.2. Eastern Europe Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Neurological Biomarkers Market
- 22.1. Russia Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Neurological Biomarkers Market
- 23.1. North America Neurological Biomarkers Market Overview
- 23.2. North America Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Neurological Biomarkers Market
- 24.1. USA Neurological Biomarkers Market Overview
- 24.2. USA Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Neurological Biomarkers Market
- 25.1. Canada Neurological Biomarkers Market Overview
- 25.2. Canada Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Neurological Biomarkers Market
- 26.1. South America Neurological Biomarkers Market Overview
- 26.2. South America Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Neurological Biomarkers Market
- 27.1. Brazil Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Neurological Biomarkers Market
- 28.1. Middle East Neurological Biomarkers Market Overview
- 28.2. Middle East Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Neurological Biomarkers Market
- 29.1. Africa Neurological Biomarkers Market Overview
- 29.2. Africa Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Neurological Biomarkers Market Competitive Landscape And Company Profiles
- 30.1. Neurological Biomarkers Market Competitive Landscape
- 30.2. Neurological Biomarkers Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
31. Neurological Biomarkers Market Other Major And Innovative Companies
- 31.1. AstraZeneca Plc
- 31.2. Abbott Laboratories
- 31.3. Boehringer Ingelheim International GmbH
- 31.4. Becton Dickinson and Company
- 31.5. Agilent Technologies Inc.
- 31.6. Grifols S.A.
- 31.7. Eisai Co. Ltd.
- 31.8. PerkinElmer Inc.
- 31.9. Illumina Inc.
- 31.10. Shimadzu Corporation
- 31.11. Waters Corporation
- 31.12. Bio-Rad Laboratories Inc.
- 31.13. Mallinckrodt Plc
- 31.14. Qiagen N.V.
- 31.15. Luminex Corporation.
32. Global Neurological Biomarkers Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Neurological Biomarkers Market
34. Recent Developments In The Neurological Biomarkers Market
35. Neurological Biomarkers Market High Potential Countries, Segments and Strategies
- 35.1 Neurological Biomarkers Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Neurological Biomarkers Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Neurological Biomarkers Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
